Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Living autologous heart valves for minimally invasive implantable procedures (LIFEVALVE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Switzerland,Germany,Netherlands,Austria,Hungary,Germany
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2009-11-01
End date: 2015-04-30
Duration (months): 66.0
Total project cost (EUR): 16062828.6
EU funding (EUR): 9876352.0
Participants: 8
Project status: CLOSED

Cardiovascular disease still represents the Killer No.1 in the EU accounting for substantial morbidity/mortality and health care cost. Heart valve replacement represents the most common surgical therapy for valvular heart disease with almost 200.000 annual implantations worldwide. Currently, heart valve prosthesis-associated problems occur in 30-35% of patients within 10 years, frequently necessitating risky re-operations. A particularly severe problem relates to children with congenital heart defects (1% of all newborns) who cannot be treated efficiently due to the lack of growths of the clinically available “artificial” valve prostheses. The principal objective of the LifeValve project is to develop a new therapeutic strategy to treat heart valve disease patients more efficiently. Two novel life science technologies will be combined: tissue engineering and minimally invasive implantation technology. In particular, the scientific and technological approach of the LifeValve project is to develop a clinically relevant tissue engineered living heart valve, with the capacity of regeneration and growths which can be implanted by minimally invasive catheter technology. First clinical trials will be enrolled in paediatric patients addressing the currently unmet dramatic medical need for growing implants. A highly interdisciplinary approach combines basic sciences, medical research, engineering and clinical practice. In addition, close industry-academia collaborations are integrated. It is expected that new knowledge applicable for a much broader field of cardiovascular diseases will be generated by the unique combination of consortium partners each representing opinion leaders in their fields. The consortium is compact comprising all the necessary expertise and skills to realize the precisely planned work in a short period of time.The close collaboration of the well interconnected LifeValve consortium will most efficiently contribute to an added value for the EU.

Keywords: regenerative medicine,tissue engineering,cardiovascular disease,heart valve
Fighting blindness of Usher syndrome: diagnosis, pathogenesis and retinal treatment (TreatRetUsher) (TREATRUSH)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,Germany,United Kingdom,Italy,Switzerland,United States,Germany,Netherlands,Germany
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-02-01
End date: 2014-01-31
Duration (months): 48.0
Total project cost (EUR): 8181653.01
EU funding (EUR): 6000000.0
Participants: 13
Project status: CLOSED

Usher syndrome (USH) is the most frequent hereditary cause of deafness associated to blindness. It is a rare disease, affecting 1 in every 10.000 individuals, with an autosomal recessive monogenic inheritance. Deafness is congenital while the retinitis pigmentosa is not detected before the age of 8 to 10. These patients suffer from a dreadful disability as their two major senses are impaired. Important scientific advances have been achieved, mostly by auditory scientists: 9 causative genes have been identified. The hearing impairment pathogenesis has been elucidated, ie, an early developmental defect of auditory sensory cells. Our project gathering scientists and physicians from both the auditory and visual fields aims : -to halt the no longer acceptable underdiagnosis of this syndrome. Because, children affected with Usher type I, the most severe form, are usually diagnosed as severely or profoundly deaf only, parents may choose visual/sign language whereas these children would have taken full advantage from an early cochlear implantation. -To make these patients benefit from gene replacement therapy in the retina that recently showed tremendous results. We propose : 1/ To develop new clinical and molecular tools and guidelines for an early diagnosis thereafter broadly disseminated. 2/To clarify the retinal pathogenesis of Usher syndrome (type I and II) by an unpreceding effort to generate animal and tissue models that will be characterised in depth by multidisciplinary investigations including innovative methods. Mouse, frog, pig in vivo models and cultured retinal explants will be used, as well as human retinal cultures. This will also provide the necessary tests to evaluate phenotype rescuing. 3/To prevent and treat the retinal defect by associated adenovirus (AAV) gene therapy. This includes optimisation of the gene transfer and selection of patients to lead to a clinical trial carried out for one or more Usher genes (USH1B, 1C, 1G &amp; USH2D)

Keywords: translational research,usher syndrom
Towards the establishment of a permanent European Virtual Institute dedicated to Malaria Research (EVIMalaR). (EVIMALAR)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Network of Excellence
Countries involved: United Kingdom,Germany,France,United Kingdom,Netherlands,Netherlands,Netherlands,United Kingdom,Sweden,Italy,United Kingdom,Greece,Switzerland,Germany,Italy,Denmark,France,Portugal,Germany,Uganda,Sudan,Nigeria,Italy,Cameroon,Germany,Australia,Germany,Spain,South Africa
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2009-10-01
End date: 2015-03-31
Duration (months): 66.0
Total project cost (EUR): 16971763.76
EU funding (EUR): 12000000.0
Participants: 39
Project status: CLOSED

This is a proposal from 55 partners from 36 institutes to form a NoE that will seek to integrate European malaria research that is directed towards a better understanding of the basic biology of the parasite, its vector and of the biology of the interactions between the parasite and both its mammalian host and vectors. All the member institutes and researchers have demonstrated both their excellence and their ability to contribute to a successful network. The structure of the proposed network significantly evolves prior concepts of network structure introducing new modes of research that have recently emerged. Comprising of 4 research clusters the core activities will include molecular cell biology of the parasite, host immunity, vector biology, population biology and systems biology. One arm of the network activities will be concerned with the timely and effective translation of research respecting the IP rights of partner institutes. The network will also contribute significantly to the production of the next generation of malaria researchers through the operation of an expanded European PhD School for malaria research based at EMBL, students enjoying two supervisors based in different member states. Bespoke training courses for PhD students and network personnel will be offered throughout the duration of the network to maximise individual potential. To create a long term benefit from network activities a limited programme of post-doctoral fellowships within the network will be established. Furthermore, individual career mentoring facilities and an alumni association will continue to guide and engage network graduates. New members will be affiliated annually on a competitive basis with an emphasis on young, emerging Principle Investigators. Through the establishment of an umbrella Foundation and active lobbying of government and non-government funding agencies as well as the establishment of a charitable profile the network will strive to become self-determining.

Keywords: malaria,plasmodium falciparum,anopheles,africa,india,human genetics,biology. immunity
EuroREACH A Handbook to Access Health Care Data for Cross-country Comparisons of Efficiency and Quality (EUROREACH)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Coordination and support actions
Countries involved: Luxembourg,France,United Kingdom,Finland,Germany,Estonia,Austria,Israel
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-03-01
End date: 2013-05-31
Duration (months): 39.0
Total project cost (EUR): 1698949.9
EU funding (EUR): 1481898.0
Participants: 9
Project status: CLOSED

EuroREACH explores how coordination among recent innovations for better health care information systems and performance measurement at a national, European and international level can lead to improved access to data for cross-country, comparative research. This will be undertaken for a broad range of questions into the efficiency, quality and equity of health care services, following a patient-centred, disease-based approach. Better integrated health care in order to improve quality and cost-effectiveness of health services across providers and care settings is a major policy concern in the EU. EuroREACH comprises coordination activities for three types of initiatives to improve data access for research: 1. European and international initiatives and research projects; 2. National practice of innovative health information and performance management systems; 3. European and international data systems and new ways to link them to national sources and to qualitative structural indicators of health care systems for comparative analysis. Expert panels and two Sounding Board Conferences will support the project, by providing input and by reviewing progress. They will also be involved in broad dissemination. Results will include guidance for researchers to data access; policy lessons on good practice of national and international performance measurement and information system design, including questions of data linkages, data protection and mapping to international classifications and data framework. The outcome will be synthesised in a handbook entitled “EuroReach: Handbook to Access Health Care Data” that will serve as a generic guide to data access for researchers, other data users and stakeholders. It will also provide guidance to policy makers, discussing options for governing and reforming information systems. A final Conference will wrap up the project’s findings.

Keywords: performance measurement,health information,data protection,chronic disease,international comparison of health systems
Systems Biology of Stem Cells and Reprogramming (SYBOSS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Denmark,Germany,Germany,Netherlands,France,Denmark,United Kingdom,United Kingdom,Germany,Germany
Call:  (FP7-HEALTH-2009-two-stage, 2009)
Start date: 2010-06-01
End date: 2015-11-30
Duration (months): 66.0
Total project cost (EUR): 13670200.4
EU funding (EUR): 10530000.0
Participants: 11
Project status: CLOSED

Stem cells are central to emerging concepts in health, medicine and therapy. The realization that specific cell reservoirs retain multipotency for tissue establishment and replenishment has implications for both the emerging field of regenerative therapy and the long standing problems of cancer, ageing and degenerative diseases. Recently the prospects for regenerative therapy have been boosted by the breakthrough finding that somatic cells can be reprogrammed into pluripotent embryonic stem (ES) cells upon expression of ES cell transcription factors. This astonishing finding further emphasizes the need to understand stem cell biology. Most of the information acquired on stem cells so far is empirical. Recent progress in systematic and computational methodologies, including seminal contributions by the applicants, permits a new approach to stem cell biology. We can now describe the systems biology of stem cells. This proposal is based on the importance of stem cells in future medicine and the need to understand the fundamental mechanisms that regulate their potential to differentiate towards specific lineages. We aim to gather the information required to understand the regulomes of key stem cells, particularly the transition between embryonic (ES) and neural (NS) cells. NS cells can be readily reprogrammed back to ES cells. We will systematically gather proteomic, transcriptomic, regulomic, live cell and cell cycle data to understand the ES – NS axis comprehensively (in both directions). We will validate the regulatory data by functional interrogation using RNAi screens and tests, complemented by quantitative fluorescent read-outs. To broaden the fundamental and medical relevance of the insights, we will pursue selected studies on other stem cells (e.g. HSCs), and their differentiated products. Thereby we will acquire a broader grasp on stem cell issues and also significantly advance mammalian systems biology.

Keywords: stem cells,pluripotency,complex diseases,pathway modeling,regulomics,genomics,epigenetics
Health Education and Community Integration: Evidence based Strategies to increase equity, integration and effectiveness of reproductive health services for poor communities in Sub Saharan Africa. (INTHEC)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: United Kingdom,Belgium,Tanzania, United Republic of,United States,Niger
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-03-01
End date: 2014-08-31
Duration (months): 54.0
Total project cost (EUR): 3625742.4
EU funding (EUR): 2750000.0
Participants: 8
Project status: CLOSED

Objectives: The research aims to improve the delivery of reproductive health (RH) services in Tanzania and Niger by generating new evidence about effective ways to strengthen the provision, uptake, equity and effectiveness of adolescent reproductive health (ARH) programmes. Background: Poor adolescent reproductive health (ARH) continues to be a major cause of morbidity and worsening poverty for the poorest people in sub-Saharan Africa. The effectiveness of ARH programmes implemented within the health and education sectors is seriously hampered by adverse prevailing cultural norms and practices within those sectors and the wider community, and by poor programme integration. Methods: The proposed research will promote equitable reproductive health (RH) service provision and improve its uptake and effectiveness by : (i) conducting a situation analysis of current community and implementer experiences of existing ARH programmes in Tanzania and Niger, identifying priority areas of weakness in RH service provision and opportunities for strengthened service uptake and integration; (ii) addressing identified weaknesses and opportunities by developing an innovative package of interventions in 4 areas: (1) workplace ARH strategy in health units; (2) RH support to teachers in schools; (3) integrated school and community guardian support to pupils; (4) enhanced community referral to health services. We will evaluate the processes and impact of the interventions through a series of rigorous process evaluation studies, which will generate new knowledge, about intervention development, and indicators of intervention processes and effect. The overall impact of the interventions will be evaluated in a population-based cluster randomised trial. Involvement as project partners of the government ministries directly responsible for ARH policy in both Niger and Tanzania, will ensure the policy-relevance of this research, and its continued impact beyond the life of this project.

Keywords: equity,community,health,integration,partnership,adolescents,reproductive health
Support Action to GMES-Africa on Earth Observation (SAGA-EO) (SAGA-EO)

Framework: FP7 — Cooperation
Programme: Space
Destination: Cross-cutting activities
Action type: Coordination and support actions
Countries involved: France,France,Germany,Senegal,Mozambique,Ghana,Côte d'Ivoire,Congo
Call:  (FP7-SPACE-2009-1, 2009)
Start date: 2010-08-01
End date: 2012-10-31
Duration (months): 27.0
Total project cost (EUR): 985773.4
EU funding (EUR): 818741.0
Participants: 8
Project status: CLOSED

The SAGA-EO proposition consists in a feasibility study on critical pieces of the puzzle of the Lisbon Declaration Implementation Plan on GMES and Africa and to complement previous experience in that field. The SAGA-EO concept is based on a sound experience of both European and African programmes dealing with environment monitoring based on information derived from Earth Observation data. The main finding driving the concept is that no programme tackles the EO field as a global approach (technological, organisational and institutional). The way to implement this EO capacity building challenge is to set-up dedicated EO networks at African national level and to link them with existing initiatives in Africa and Europe. In SAGA-EO, the EO network approach will constitute the ground where to build the thematic networks. The main purpose and objectives of the SAGA-EO project is to design and implement the network organisation and associated technology and to prove it in five countries trough the following the five main actions : Action 1: To define African Earth Observation network organisational models at national level Action 2: To define generic technological solutions, compatible with existing standards, to receive, archive, share, disseminate, advise on EO data Action 3: To implement a proof of concept of the organisation &amp; technology in few countries Action 4: To write a methodology for the implementation of the future operational networks and system Action 5: To cooperate with the GMES Africa Working Groups in the preparation of the EU-AU Join Strategic Partnership action plan.

Keywords: gmes-africa,earth observation,organisational model,national networks,thematic community,capacity building
European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Belgium,Germany,Belgium,Italy,Austria,United Kingdom,United Kingdom,United Kingdom,Spain,France,France,United States
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-05-01
End date: 2015-04-30
Duration (months): 60.0
Total project cost (EUR): 7934618.4
EU funding (EUR): 5983379.0
Participants: 15
Project status: CLOSED

EFACTS (the European Friedreich’s Ataxia Consortium for Translational Studies) assembles a body of expertise to adopt a translational research strategy for the rare autosomal recessive neurological disease, Friedreich’s ataxia (FRDA). FRDA is a severely debilitating disease that leads to loss of the ability to walk and dependency for all activities. Some patients have cardiomyopathy that can cause premature death, visual and auditory loss, kyphoscoliosis, pes cavus, diabetes. Onset is usually in childhood, but it may vary from infancy to adulthood. FRDA involves child health and ageing aspects. FRDA affected individuals and clinical specialists are dispersed. This is a hindrance for patients to receive the care they need, and for clinicians and researchers to make progress. EFACTS has been created to move past this limitation. EFACTS strongly believes that, 12 years after European researchers discovered the FRDA gene, frataxin, when new treatments for FRDA are being developed, the time is ripe to invest in FRDA research in a concerted Europe-wide fashion. EFACTS gathers the critical mass of researchers and clinicians to exploit the patient base, research reagents and knowledge for progress. This comes when IT can act as a crucial support for collaborative work in collecting patient data and material, making it available to leading researchers for advanced analysis, research and drug development. This project proposal has the following scientific and technological objectives: 1. Comprehensively populate a European FRDA database, linked to a bio bank; 2. Define a panel of clinical assessment tools; 3. Build on the knowledge base of frataxin structure and function; 4. Build on the knowledge base of the pathogenic cascade; 5. Build on the knowledge base of epigenetic mechanisms of frataxin silencing; 6. Develop new cellular and animal models for the study of FRDA; 7. Identify FRDA biomarkers; 8. Identify genetic modifiers of FRDA; 9. Develop therapeutics for FRDA.

Keywords: ataxia,translational research,animal and cellular models,pathogenesis,epigenetics,therapy
The Railway-Industry Partnership for Integrated Security of Rail Transport (PROTECTRAIL)

Framework: FP7 — Cooperation
Programme: Security
Destination: Increasing the Security of infrastructures and utilities
Action type: Collaborative project
Countries involved: Italy,Netherlands,Italy,France,Germany,France,Belgium,Israel,Belgium,France,United Kingdom,France,Poland,France,France,Türkiye,France,Germany,Germany,Slovakia,Lithuania
Call:  (FP7-SEC-2009-1, 2009)
Start date: 2010-09-01
End date: 2014-06-30
Duration (months): 46.0
Total project cost (EUR): 21644416.6
EU funding (EUR): 13115064.0
Participants: 31
Project status: CLOSED

Facing the problem of enhancing the railway security with a systematic top-down approach (i.e. to search for an all-inclusive solution valid for all the conceivable threat scenarios) is judged by PROTECTRAIL members too ambitious even if it could generate potential economies of scale and effort rationalisation. The proposed PROTECTRAIL approach is therefore to split the problem of making the railway more secure into smaller asset-specific security problems (missions) for which it is easier to reach satisfactory solutions applicable and usable in different threat scenarios. Each sub-mission could be therefore better oriented to particularly significant areas of interest, resulting from risk analysis or from rail operator priorities. In a clear view of scope and performance goals, for each sub mission it will be easier to define, research and develop solutions in terms of architectures, technology deployment, as well as the necessary procedures, organizations to manage the specific issue. The PROTECTRAIL challenge is therefore to make interoperable the single asset-specific solutions and to conceive and design a modular architectural framework where each asset-specific solution can be “plugged”, that is the basis to assure a streamlined process of federation, integration and interoperability of respective solutions. The PROTECTRAIL project will address the following security sub-missions: protection of signal and power distribution systems against any terrorism act, track clearance, clearance of trains before and after daily use, staff clearance, luggage clearance control, passenger clearance control, freight clearance control, tracking and monitoring of rolling stock carrying dangerous goods, protection of communication and information systems, stations, buildings and infrastructure protection.

Keywords: security,railway,protection of critical infrastructures,integration,interoperability